Key result
APOLO-VT trial tests integrated ECGi and EAM mapping to reduce 12-month VT recurrence after ablation.
Why the study?
VT recurrence remains common after ablation due to incomplete substrate identification, and structural imaging and ECGi are not routinely integrated into a workflow-ready ablation strategy.
Does an integrated multimodal mapping workflow combining ECGi and EAM prevent VT recurrence in adults with structural heart disease undergoing VT ablation?
Does an integrated multimodal mapping workflow combining ECGi and EAM prevent VT recurrence in adults with structural heart disease undergoing VT ablation?
The APOLO-VT trial will evaluate the feasibility and clinical impact of a novel workflow integrating noninvasive ECG imaging with invasive electroanatomical mapping to guide and verify ventricular tachycardia ablation.
Answers are grounded in this paper and cite their sources.
Integrated multimodal VT mapping may enhance substrate identification; leaves open clinical impact pending randomized validation.
Background VT ablation reduces arrhythmic burden and ICD therapies, yet VT recurrence remains common. A key limitation is incomplete identification and durable elimination of the slow‐conduction substrate. Structural imaging and ECGi provide complementary information but are not routinely integrated into a workflow‐ready ablation strategy. Objective APOLO‐VT aims to evaluate the feasibility, safety, and clinical impact of an integrated multimodal mapping workflow combining noninvasive structural and functional substrate characterization using ECGi with invasive EAM to support VT ablation targeting and verification. Methods APOLO‐VT is an interventional, prospective, single‐center investigation enrolling 60 adults with structural heart disease undergoing VT ablation. Scar/border‐zone characterization will be derived from LGE‐CMR (or CT when contraindicated) and integrated with ECGi maps and invasive EAM. Noninvasively defined targets will be ablated, followed by S3‐paced ECGi remapping; persistent deceleration zones will prompt additional ablation. If the S3‐paced ECGi map is free of deceleration zones, programmed stimulation and an invasive S3‐paced map will be performed to confirm endpoint achievement. Follow‐up will be 12 months. Results The primary endpoint is VT recurrence at 12 months. Secondary endpoints include acute non‐inducibility, procedural efficiency, safety outcomes, mortality, and mechanistic concordance analyses. Conclusions APOLO‐VT will provide prospective feasibility, safety, mechanistic, and exploratory outcome data on a standardized noninvasive‐to‐invasive multimodal strategy with iterative post‐ablation functional noninvasive reassessment.
No takes yet. Share an insight, caveat, or question.
Bhagirath et al. (2026) studied Ventricular Tachycardia in structural heart disease (n=60). Integrated multimodal mapping workflow (ECGi with invasive EAM) was evaluated on VT recurrence at 12 months. The APOLO-VT trial will evaluate an integrated multimodal mapping workflow combining ECGi and invasive EAM for VT ablation in 60 adults, with a primary endpoint of VT recurrence at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: